249 related articles for article (PubMed ID: 38276943)
1. Advances in Screening for Barrett Esophagus and Esophageal Adenocarcinoma.
Vantanasiri K; Kamboj AK; Kisiel JB; Iyer PG
Mayo Clin Proc; 2024 Mar; 99(3):459-473. PubMed ID: 38276943
[TBL] [Abstract][Full Text] [Related]
2. Innovations in Screening Tools for Barrett's Esophagus and Esophageal Adenocarcinoma.
Bell MG; Iyer PG
Curr Gastroenterol Rep; 2021 Oct; 23(12):22. PubMed ID: 34654955
[TBL] [Abstract][Full Text] [Related]
3. Novel Screening Tests for Barrett's Esophagus.
Codipilly DC; Iyer PG
Curr Gastroenterol Rep; 2019 Jul; 21(9):42. PubMed ID: 31346777
[TBL] [Abstract][Full Text] [Related]
4. Goblet Cell Ratio in Combination with Differentiation and Stem Cell Markers in Barrett Esophagus Allow Distinction of Patients with and without Esophageal Adenocarcinoma.
Schellnegger R; Quante A; Rospleszcz S; Schernhammer M; Höhl B; Tobiasch M; Pastula A; Brandtner A; Abrams JA; Strauch K; Schmid RM; Vieth M; Wang TC; Quante M
Cancer Prev Res (Phila); 2017 Jan; 10(1):55-66. PubMed ID: 27807078
[TBL] [Abstract][Full Text] [Related]
5. Molecular biomarkers added to image-enhanced endoscopic imaging: will they further improve diagnostic accuracy?
Krishnamoorthi R; Iyer PG
Best Pract Res Clin Gastroenterol; 2015 Aug; 29(4):561-73. PubMed ID: 26381302
[TBL] [Abstract][Full Text] [Related]
6. Screening and surveillance of Barrett's esophagus.
Michalak J; Bansal A; Sharma P
Curr Gastroenterol Rep; 2009 Jun; 11(3):195-201. PubMed ID: 19463219
[TBL] [Abstract][Full Text] [Related]
7. Endoscopic Screening for Barrett's Esophagus and Esophageal Adenocarcinoma: Rationale, Candidates, and Challenges.
Kamboj AK; Katzka DA; Iyer PG
Gastrointest Endosc Clin N Am; 2021 Jan; 31(1):27-41. PubMed ID: 33213798
[TBL] [Abstract][Full Text] [Related]
8. Point-Counterpoint: Screening and Surveillance for Barrett's Esophagus, Is It Worthwhile?
Otaki F; Iyer PG
Dig Dis Sci; 2018 Aug; 63(8):2081-2093. PubMed ID: 29713986
[TBL] [Abstract][Full Text] [Related]
9. Recent developments in esophageal adenocarcinoma.
Lagergren J; Lagergren P
CA Cancer J Clin; 2013; 63(4):232-48. PubMed ID: 23818335
[TBL] [Abstract][Full Text] [Related]
10. 2017 David Sun Lecture: Screening and Surveillance of Barrett's Esophagus: Where Are We Now and What Does the Future Hold?
Falk GW
Am J Gastroenterol; 2019 Jan; 114(1):64-70. PubMed ID: 30361622
[TBL] [Abstract][Full Text] [Related]
11. [Screening for adenocarcinoma in Barrett's esophagus: yes or no, when and how?].
Sostres C; Lacarta P; Lanas A
Gastroenterol Hepatol; 2013 Oct; 36(8):520-6. PubMed ID: 23453559
[TBL] [Abstract][Full Text] [Related]
12. Screening for Barrett's Esophagus.
di Pietro M; Chan D; Fitzgerald RC; Wang KK
Gastroenterology; 2015 May; 148(5):912-23. PubMed ID: 25701083
[TBL] [Abstract][Full Text] [Related]
13. Magnitude and Time-Trends of Post-Endoscopy Esophageal Adenocarcinoma and Post-Endoscopy Esophageal Neoplasia in a Population-Based Cohort Study: The Nordic Barrett's Esophagus Study.
Wani S; Holmberg D; Santoni G; Kauppila JH; Farkkila M; von Euler-Chelpin M; Shaheen NJ; Lagergren J
Gastroenterology; 2023 Oct; 165(4):909-919.e13. PubMed ID: 37279832
[TBL] [Abstract][Full Text] [Related]
14. Who Deserves Endoscopic Screening for Esophageal Neoplasia?
Blevins CH; Iyer PG
Gastrointest Endosc Clin N Am; 2017 Jul; 27(3):365-378. PubMed ID: 28577762
[TBL] [Abstract][Full Text] [Related]
15. Management of cancer risk in Barrett's esophagus.
Tan A; Macrae F
J Gastroenterol Hepatol; 2011 Oct; 26(10):1485-92. PubMed ID: 21592226
[TBL] [Abstract][Full Text] [Related]
16. Incidence of Esophageal Adenocarcinoma and Causes of Mortality After Radiofrequency Ablation of Barrett's Esophagus.
Wolf WA; Pasricha S; Cotton C; Li N; Triadafilopoulos G; Muthusamy VR; Chmielewski GW; Corbett FS; Camara DS; Lightdale CJ; Wolfsen H; Chang KJ; Overholt BF; Pruitt RE; Ertan A; Komanduri S; Infantolino A; Rothstein RI; Shaheen NJ
Gastroenterology; 2015 Dec; 149(7):1752-1761.e1. PubMed ID: 26327132
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Serum Glycoprotein Biomarker Candidates for Detection of Esophageal Adenocarcinoma and Surveillance of Barrett's Esophagus.
Shah AK; Hartel G; Brown I; Winterford C; Na R; Cao KL; Spicer BA; Dunstone MA; Phillips WA; Lord RV; Barbour AP; Watson DI; Joshi V; Whiteman DC; Hill MM
Mol Cell Proteomics; 2018 Dec; 17(12):2324-2334. PubMed ID: 30097534
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Uncertainty in Barrett's Esophagus Progression Rates on Hypothetical Screening and Treatment Decisions.
Kroep S; Lansdorp-Vogelaar I; van der Steen A; Inadomi JM; van Ballegooijen M
Med Decis Making; 2015 Aug; 35(6):726-33. PubMed ID: 25277672
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic biomarkers in esophageal cancer.
Kaz AM; Grady WM
Cancer Lett; 2014 Jan; 342(2):193-9. PubMed ID: 22406828
[TBL] [Abstract][Full Text] [Related]
20. Australian clinical practice guidelines for the diagnosis and management of Barrett's esophagus and early esophageal adenocarcinoma.
Whiteman DC; Appleyard M; Bahin FF; Bobryshev YV; Bourke MJ; Brown I; Chung A; Clouston A; Dickins E; Emery J; Eslick GD; Gordon LG; Grimpen F; Hebbard G; Holliday L; Hourigan LF; Kendall BJ; Lee EY; Levert-Mignon A; Lord RV; Lord SJ; Maule D; Moss A; Norton I; Olver I; Pavey D; Raftopoulos S; Rajendra S; Schoeman M; Singh R; Sitas F; Smithers BM; Taylor AC; Thomas ML; Thomson I; To H; von Dincklage J; Vuletich C; Watson DI; Yusoff IF
J Gastroenterol Hepatol; 2015 May; 30(5):804-20. PubMed ID: 25612140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
